Mohammed Aya Osama, Rady Hanaa I
Department of Pediatrics, Faculty of Medicine, Cairo University, Cairo, Egypt.
Pediatric Intensive Care Unit, Cairo University Children Hospital, Cairo, Egypt.
Acute Crit Care. 2024 Feb;39(1):70-77. doi: 10.4266/acc.2023.00654. Epub 2024 Feb 1.
Extracorporeal blood-purification techniques are frequently needed in the pediatric intensive care unit (PICU), yet data on their clinical application are lacking. This study aims to review the indications, rate of application, clinical characteristics, complications, and outcomes of patients undergoing extracorporeal blood purification (i.e., by continuous renal replacement therapy [CRRT] or therapeutic plasma exchange [TPE]) in our PICU, including before the coronavirus disease 2019 (COVID-19) pandemic in 2019 and during the pandemic from 2020 to 2022.
This study included children admitted for extracorporeal blood-purification therapy in the PICU. The indications for TPE were analyzed and compared to the American Society for Apheresis categories.
In 82 children, 380 TPE sessions and 37 CRRT sessions were carried out children, with 65 patients (79%) receiving TPE, 17 (20.7%) receiving CRRT, and four (4.8%) receiving both therapies. The most common indications for TPE were neurological diseases (39/82, 47.5%), followed by hematological diseases (18/82, 21.9%). CRRT was mainly performed for patients suffering from acute kidney injury. Patients with neurological diseases received the greatest number of TPE sessions (295, 77.6%). Also, the year 2022 contained the greatest number of patients receiving extracorporeal blood-purification therapy (either CRRT or TPE).
The use of extracorporeal blood-purification techniques increased from 2019 through 2022 due to mainly autoimmune dysregulation among affected patients. TPE can be safely used in an experienced PICU. No serious adverse events were observed in the patients that received TPE, and overall survival over the 4 years was 86.5%.
儿科重症监护病房(PICU)经常需要体外血液净化技术,但缺乏关于其临床应用的数据。本研究旨在回顾在我们的PICU接受体外血液净化(即通过持续肾脏替代疗法[CRRT]或治疗性血浆置换[TPE])的患者的适应症、应用率、临床特征、并发症和结局,包括2019年冠状病毒病(COVID-19)大流行之前的2019年以及2020年至2022年大流行期间。
本研究纳入了在PICU接受体外血液净化治疗的儿童。分析了TPE的适应症,并与美国单采学会的类别进行比较。
82名儿童共进行了380次TPE治疗和37次CRRT治疗,其中65例患者(79%)接受TPE治疗,17例(20.7%)接受CRRT治疗,4例(4.8%)接受两种治疗。TPE最常见的适应症是神经系统疾病(39/82,47.5%),其次是血液系统疾病(18/82,21.9%)。CRRT主要用于急性肾损伤患者。神经系统疾病患者接受的TPE治疗次数最多(295次,77.6%)。此外,2022年接受体外血液净化治疗(CRRT或TPE)的患者数量最多。
由于受影响患者主要存在自身免疫失调,2019年至2022年期间体外血液净化技术的使用有所增加。TPE可以在经验丰富的PICU中安全使用。接受TPE治疗的患者未观察到严重不良事件,4年总体生存率为86.5%。